2 results match your criteria: "The Kenneth S Warren Institute and Warren Pharmaceuticals[Affiliation]"
Kidney Int
July 2006
The Kenneth S Warren Institute and Warren Pharmaceuticals, Ossining, New York 10562, USA.
A greatly expanded understanding of the biology of endogenous erythropoietin (EPO) has emerged since the early 1990s. Originally viewed as the renal hormone dedicated to erythrocyte production, it is now clear that EPO is produced locally by many other tissues in response to physical or metabolic stress. In its autocrine-paracrine roles, EPO mediates preconditioning (ischemic tolerance) and specifically limits the destructive potential of tumor necrosis factor alpha and other proinflammatory cytokines in the brain, heart, kidney, and other tissues.
View Article and Find Full Text PDFNat Rev Neurosci
June 2005
The Kenneth S. Warren Institute and Warren Pharmaceuticals, Inc., 712 Kitchawan Road, Ossining, New York 10562, USA.
Erythropoietin mediates an evolutionarily conserved, ancient immune response that limits damage to the heart, the nervous system and other tissues following injury. New evidence indicates that erythropoietin specifically prevents the destruction of viable tissue surrounding the site of an injury by signalling through a non-haematopoietic receptor. Engineered derivatives of erythropoietin that have a high affinity for this receptor have been developed, and these show robust tissue-protective effects in diverse preclinical models without stimulating erythropoiesis.
View Article and Find Full Text PDF